APA (7th ed.) Citation

(2019). Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Correction: Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-modifying Antirheumatic Drugs (cDMARDs) in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors. BMJ Publishing Group, 2019.

MLA (9th ed.) Citation

Correction: Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-modifying Antirheumatic Drugs (cDMARDs) in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors. BMJ Publishing Group, 2019.